Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02690324 : The Development of Skin Adhesive Patches for the Monitoring and Prediction of Mental Disorders
PhaseN/A
AgesMin: 20 Years Max: N/A
Eligibility
Inclusion Criteria:

- the existence of a current Major depressive disorder or panic disorder during the
screening and baseline visits, per the Mini-International Neuropsychiatric Interview
(Sheehan et al., 1998) according to the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-5)

- scored at least 16 on the HDRS-17 (Hamilton, 1960) for MDD and 7 on the Panic
disorder severity scale for panic disorder patients at the baseline visits.

Exclusion Criteria:

- Patients who had psychotic disorder (e.g., schizophrenia or delusional disorder),
bipolar affective disorder,active alcohol or drug use disorder, neurological illness
including significant cognitive impairment or Parkinson's disease, mental
retardation, significant medical conditions, epilepsy, histories of alcohol or drug
dependence, personality disorders, or brain damages

- patients who were at serious risk for suicide of homicide
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02690324      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740